Neovasc Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference
January 04 2021 - 4:05PM
via NewMediaWire -- Neovasc Inc. (Nasdaq, TSX: NVCN), today
announced its participation in the H.C. Wainwright BioConnect 2021
Virtual Conference, which takes place January 11-14, 2021.
Neovasc President and Chief Executive Officer Fred Colen, Chief
Operating Officer Bill Little, and Chief Financial Officer Chris
Clark will be available for one-on-one investor meetings during the
event; meetings may be requested through H.C.
Wainwright. Additionally, a webcast of Neovasc’s recorded
company presentation will be available on demand via the H.C.
Wainwright conference site beginning at 6:00 am ET on January 11,
and on the Neovasc website at https://www.neovasc.com/presos/
About Neovasc Inc.
Neovasc is a specialty medical device company that
develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is not currently commercially
available in the United States and has been commercially available
in Europe since 2015, and Tiara, for the transcatheter treatment of
mitral valve disease, which is currently under clinical
investigation in the United States, Canada, Israel and Europe. For
more information, visit: www.neovasc.com.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
Sean.Leous@icrinc.com
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Apr 2023 to Apr 2024